NovaBay Pharmaceuticals, Inc. (NBY) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NovaBay Pharmaceuticals, Inc. (NBY:NYSE), powered by AI.

Current Price
$1.11
P/E Ratio
-0.0
Market Cap
1M
Sector
Healthcare
What is the NovaBay Pharmaceuticals, Inc. stock price forecast?

NovaBay Pharmaceuticals, Inc. is currently trading at $1.11. View real-time AI analysis on Alpha Lenz.

What is NovaBay Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for NovaBay Pharmaceuticals, Inc. on Alpha Lenz.

What is NovaBay Pharmaceuticals, Inc.'s P/E ratio?

NovaBay Pharmaceuticals, Inc.'s P/E ratio is -0.0.

NovaBay Pharmaceuticals, Inc.

NYSE · NBY
$1.11+0.03(+2.78%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about NovaBay Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

NovaBay Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 199.6%.

Ask for details

Company Overview

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of non-antibiotic anti-infective consumer products. It primarily operates in the field of eye care under the proprietary name Avenova®, which is a lid and lash hygiene product designed to maintain ocular health and comfort. The company places a strong emphasis on innovation within the pharmaceutical landscape, focusing on solutions that address prevalent health issues without relying on traditional antibiotics, thereby contributing to the significant global effort in combating antibiotic resistance. Operating in the healthcare sector, NovaBay Pharmaceuticals is pivotal in delivering effective consumer-friendly health solutions, catering to both the general public and healthcare professionals. Besides ophthalmology, its product lines also extend into dermatology, with offerings that provide relief and treatment for various skin conditions. Based in California, NovaBay Pharmaceuticals continues to enhance its market presence through strategic partnerships and direct consumer sales, reinforcing its commitment to improving health standards and responding dynamically to evolving medical needs.

CEOMr. David Elliot Lazar
SectorHealthcare
IndustryBiotechnology
Employees13

Company Statistics

FY 2025

Profile

$1.29MMarket Cap
$0.00Revenue
0.00Shares Out
13Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-0.00P/E
-0.00P/B
N/AEV/Sales
0.79EV/EBITDA
-0.15P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-10126.51%ROA
199.63%ROE
-10299.95%ROIC

Financial Health

$7.96MCash & Cash Equivalents
$632.89MNet Debt
-101.43%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

NovaBay Pharmaceuticals, Inc. (ticker: NBY) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 13 employees. Market cap is $1M.

The current price is $1.11 with a P/E ratio of -0x and P/B of -0x.

ROE is 199.63%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
NovaBay Pharmaceuticals, Inc. (NBY) Stock Forecast 2026 $1.11 — Price, Financials & Analyst Targets | Alpha Lenz